세계의 불활성화 폴리오바이러스 백신 시장 : 현황 분석 및 예측(2023-2030년)

The inactivated polio vaccine is a safe and effective vaccine to prevent polio disease. Polio is a highly contagious disease caused by poliovirus that infects the human immune system. It contains killed or "inactivated" poliovirus strains. IPV is not a live virus vaccine, so it cannot cause polio or any other illness. It is made from killed virus particles, which are then weakened to the point where they cannot replicate or cause infection. This makes it safe for people with weakened immune systems. The vaccine is injected into the body to stimulate the immune system to make antibodies to fight off the virus. The vaccine is usually given through an injection into the arm, such as those undergoing chemotherapy or taking immunosuppressive drugs, to receive the vaccine. Factors such as a surge in government and community awareness programs concerning the significance of vaccination are driving the market. For instance, in 2020, the Global Polio Eradication Initiative (GPEI) launched a review of the strategy polio eradication strategy 2022 - 2026 for polio eradication. The strategy provides a roadmap for achieving a lasting and sustainable world free of poliovirus. Other factors, including advancements in medical care framework, and expanded speculations from the public authority, public, and confidential areas in medical services divisions are driving the development of the market during the forecast period. Moreover, the rising spotlight on eliminating polio globally and the introduction of new polio-eradicating initiatives driven by associations like the World Health Organization (WHO) further reinforce market development. For instance, in 2020, the Centers for Disease Control and Prevention estimated global coverage with more than 3 doses of Pol3 for infants <1 year of age vaccinated during routine childhood immunizations with 83% of children receiving more than 1 full dose (IPV1) and 80% receiving more than 2 fractional doses (IPV1).

The Global Inactivated Poliovirus Vaccine Market is expected to grow at a steady rate of around 5.1% owing to the increase in effective vaccines offered by pharmaceutical companies due to the constant growth in polio cases which needs to be controlled. For instance, according to the Centers for Disease Control and Prevention in August 2022, two doses of inactivated polio vaccine (IPV) were 90% effective or more against paralytic polio; three doses were 99% to 100% effective. Many new therapies are being introduced to treat this deadly polio virus. Several other factors, such as the establishment of potential pharmaceutical companies, the introduction of better therapeutics and their cost-effectiveness, and government initiatives are also driving this market of global inactivated poliovirus vaccines at a steady rate. For instance, Serum Institute is a vaccine manufacturer established in India and is one of the largest vaccine manufacturers in the world. It manufactures a variety of vaccines, including the IPV vaccine. The IPV, also known as the IPV-BB vaccine, is renowned for its superior quality and cost-effectiveness. Over the years, Serum Institute has experienced significant market expansion, both domestically and internationally.

Based on type, the market is bifurcated into human diploid cells and monkey kidney cells. The human diploid cell segment held the maximum share in the global market of inactivated poliovirus vaccines 2022. This segment dominated the market because of the higher efficacy. These are the most widely used type of vaccine. Human diploid cell (HDC) vaccines are produced using human diploid (HDP) cell cultures. The development of this cell line for polio vaccines began when it became apparent that animal cells were unsuitable for producing polioviruses. Various regions of the world have licensed and adapted the usage of such vaccines. For instance, the Poliovirus vaccine Inactivated (human diploid cell) vaccine Poliovax has been granted a vaccine license in the U.S. by the Food and Drug Administration (FDA). Hence, for the above reasons, the human diploid cell segment held a significant market share in 2022.

Based on the distribution channel, the market is bifurcated into public and private. The private segment is expected to hold a significant share of the market in the forecast period owing to private health insurance providing coverage for all vaccinations, including vaccinations for infants under six months of age. Apart from this, the constant number of cases of polio and workload is boosting the hospital's patient load and impelling this segment's growth. With constant efforts, the world has seen success in controlling polio spread to a major extent. For instance, according to the World Health Organization (WHO), in October of 2023, over 20 million people walking today would otherwise be paralyzed. Vaccine-systematic vitamin A administration during immunization activities has prevented an estimated 1,500,000 childhood deaths in 2020 alone. Africa became the 5th region to be declared wild Polio-free in 2020. Hence, amongst distribution channels, the private category is expected to witness a higher CAGR during the forecast period.

For a better understanding of the market adoption of inactivated poliovirus vaccine, the market is analyzed based on its worldwide presence in countries such as North America (U.S., Canada, and Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America dominated the global inactivated poliovirus vaccine market in 2022 due to the constant polio cases, surge in vaccination rate, and rising investments in developing effective therapeutics. Government organizations are initiating polio awareness programs to provide efficient care to patients. For instance, according to an article published in Frontiers Media S.A. in July 2020, vaccines were developed, licensed, and introduced as part of large systematic immunization programs that began to address health disparities in North America. Thus, North America held a significant share of the market in the year 2022.

Some of the major players operating in the market include: Bharat Biotech.; BIO-MED; Serum Institute of India Pvt. Ltd.; Kedrion; GSK plc.; Bilthoven Biologicals; Merck & Co.; Inc.; Pfizer Inc.; Cadila Pharmaceuticals; Berna Biotech Pharma GmbH.

TABLE OF CONTENTS

1 MARKET INTRODUCTION

• 1.1. Market Definitions
• 1.2. Main Objective
• 1.3. Stakeholders
• 1.4. Limitation

2 RESEARCH METHODOLOGY OR ASSUMPTION

• 2.1. Research Process of the Global Inactivated Poliovirus Vaccine Market
• 2.2. Research Methodology of the Global Inactivated Poliovirus Vaccine Market
• 2.3. Respondent Profile

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 IMPACT OF COVID-19 ON THE GLOBAL INACTIVATED POLIOVIRUS VACCINE MARKET

6 GLOBAL INACTIVATED POLIOVIRUS VACCINE MARKET REVENUE (USD BN), 2020-2030F

7 MARKET INSIGHTS BY TYPE

• 7.1. Human Diploid Cell
• 7.2. Monkey Kidney Cell

8 MARKET INSIGHTS BY DISTRIBUTION CHANNEL

• 8.1. Public
• 8.2. Private

9 MARKET INSIGHTS BY REGION

• 9.1. North America
  • 9.1.1. U.S.
  • 9.1.2. Canada
  • 9.1.3. Rest of North America
• 9.2. Europe
  • 9.2.1. Germany
  • 9.2.2. U.K.
  • 9.2.3. France
  • 9.2.4. Italy
  • 9.2.5. Spain
  • 9.2.6. Rest of Europe
• 9.3. Asia-Pacific
  • 9.3.1. China
  • 9.3.2. Japan
  • 9.3.3. India
  • 9.3.4. Rest of Asia-Pacific
• 9.4. Rest of World

10 GLOBAL INACTIVATED POLIOVIRUS VACCINE MARKET DYNAMICS

• 10.1. Market Drivers
• 10.2. Market Challenges
• 10.3. Impact Analysis

11 GLOBAL INACTIVATED POLIOVIRUS VACCINE MARKET OPPORTUNITIES

12 GLOBAL INACTIVATED POLIOVIRUS VACCINE MARKET TRENDS

13 DEMAND AND SUPPLY-SIDE ANALYSIS

• 13.1. Demand Side Analysis
• 13.2. Supply Side Analysis

14 VALUE CHAIN ANALYSIS

15 COMPETITIVE SCENARIO

• 15.1. Competitive Landscape
  • 15.1.1. Porters Fiver Forces Analysis

16 COMPANY PROFILED

• 16.1. Bharat Biotech.
• 16.2. BIO-MED
• 16.3. Serum Institute of India Pvt. Ltd.
• 16.4. Kedrion
• 16.5. GSK plc.
• 16.6. Bilthoven Biologicals
• 16.7. Merck & Co., Inc.
• 16.8. Pfizer Inc.
• 16.9. Cadila Pharmaceuticals
• 16.10. Berna Biotech Pharma GmbH

17 DISCLAIMER